


## ML365

Cat. No.:	HY-12345
CAS No.:	947914-18-3
Molecular Formula:	C <sub>22</sub> H <sub>20</sub> N <sub>2</sub> O <sub>3</sub>
Molecular Weight:	360.41
Target:	Potassium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Powder    -20°C    3 years 4°C        2 years In solvent   -80°C    2 years -20°C    1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (277.46 mM)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.7746 mL	13.8731 mL	27.7462 mL
	5 mM		0.5549 mL	2.7746 mL	5.5492 mL
	10 mM		0.2775 mL	1.3873 mL	2.7746 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 3 mg/mL (8.32 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 3 mg/mL (8.32 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

ML365 is a selective two-pore domain potassium channel KCNK3/TASK1 inhibitor, with an IC<sub>50</sub> of 4 nM. ML365 acts as a pharmacological tool that can be used to examine the specific roles of TASK1 channels<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 4 nM (TASK1/KCNK3), 390 nM (TASK3/KCNK9)<sup>[1]</sup>

#### In Vitro

ML365 blocks TASK1 channels in both the thallium influx fluorescent assay (IC<sub>50</sub> = 4 nM) and an automated electrophysiology assay (IC<sub>50</sub> = 16 nM)<sup>[1]</sup>.  
 ML365 displays little or no inhibition at 30 μM of more distantly related potassium channels, Kir2.1, potassium voltage-gated channel, KQT-like subfamily, member 2 (KCNQ2), and human ether-a go-go-related gene (hERG)<sup>[1]</sup>.

---

ML365 does not exhibit acute toxicity in cell-based assays at concentrations up to 30  $\mu\text{M}$ <sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Acta Pharmacol Sin. 2021 Aug 2.
- J Am Heart Assoc. 2017 Sep 9;6(9). pii: e006465.
- Graduate School of Arts and Sciences. Columbia University. 2017 Jun.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Zou B, et al. ML365: Development of Bis-Amides as Selective Inhibitors of the KCNK3/TASK1 Two Pore Potassium Channel. Probe Reports from the NIH Molecular Libraries Program [Internet].

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA